Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

In addition to J.P. Morgan, Pfizer also received a Hold from HSBC’s Rajesh Kumar in a report issued on July 6. However, on July 3, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE).

Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this article, we will summarize the bulls’ thesis on PFE.

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Keep in mind, though, that many steep dividend yields are due to the underlying stock having fallen, and Pfizer is a clear example of that phenomenon. Its shares were recently down about 18% over the ...

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...